Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Advances in Natural Killer Cell Therapies for Breast Cancer Publisher Pubmed



Kiaei SZF1 ; Nouralishahi A2 ; Ghasemirad M3 ; Barkhordar M4 ; Ghaffari S5 ; Kheradjoo H6 ; Saleh M7 ; Mohammadzadehsaliani S8 ; Molaeipour Z9
Authors

Source: Immunology and Cell Biology Published:2023


Abstract

Breast cancer (BC) is the most common cause of cancer death in women. According to the American Cancer Society's yearly cancer statistics, BC constituted almost 15% of all the newly diagnosed cancer cases in 2022 for both sexes. Metastatic disease occurs in 30% of patients with BC. The currently available treatments fail to cure metastatic BC, and the average survival time for patients with metastatic BC is approximately 2 years. Developing a treatment method that terminates cancer stem cells without harming healthy cells is the primary objective of novel therapeutics. Adoptive cell therapy is a branch of cancer immunotherapy that utilizes the immune cells to attack cancer cells. Natural killer (NK) cells are an essential component of innate immunity and are critical in destroying tumor cells without prior stimulation with antigens. With the advent of chimeric antigen receptors (CARs), the autologous or allogeneic use of NK/CAR–NK cell therapy has raised new hopes for treating patients with cancer. Here, we describe recent developments in NK and CAR–NK cell immunotherapy, including the biology and function of NK cells, clinical trials, different sources of NK cells and their future perspectives on BC. © 2023 the Australian and New Zealand Society for Immunology, Inc.
Related Docs
View other Related Docs
1. Targeting Immune Checkpoints: How to Use Natural Killer Cells for Fighting Against Solid Tumors, Cancer Communications (2023)
2. The Nexus of Natural Killer Cells and Melanoma Tumor Microenvironment: Crosstalk, Chemotherapeutic Potential, and Innovative Nk Cell-Based Therapeutic Strategies, Cancer Cell International (2023)
3. Engaging Stemness Improves Cancer Immunotherapy, Cancer Letters (2023)
Experts (# of related papers)
View all Related Experts
Mazdak Ganjalikhani Hakemi (5)
Nafiseh Esmaeil (4)
Other Related Docs
4. Advances in Bioengineered Car T/Nk Cell Therapy for Glioblastoma: Overcoming Immunosuppression and Nanotechnology-Based Strategies for Enhanced Car T/Nk Cell Therapy, Bioengineering and Translational Medicine (2024)
5. A Novel Car Expressing Nk Cell Targeting Cd25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers, Frontiers in Oncology (2021)
6. Cancer Exosomes and Natural Killer Cells Dysfunction: Biological Roles, Clinical Significance and Implications for Immunotherapy, Molecular Cancer (2022)
7. More Balance Toward Activating Receptors and Cytotoxic Activity of Nk Cells Ex Vivo Differentiated From Human Umbilical Cord Blood-Derived Cd34+ Stem Cells in Comparison With Peripheral Blood Nk Cells, Heliyon (2024)
8. Flip-Flops of Natural Killer Cells in Autoimmune Diseases Versus Cancers: Immunologic Axis, Journal of Cellular Physiology (2019)
9. Optimization of in Vitro Expansion and Activation of Human Natural Killer Cells Against Breast Cancer Cell Line, Avicenna Journal of Medical Biotechnology (2020)
10. Investigation of Kir/Hla Relationship and Other Clinical Variables After T-Cell-Replete Haploidentical Bone Marrow Transplantation in Patients With Acute Myeloid Leukemia (Aml), BMC Immunology (2023)
11. The Influence of Kir Gene Polymorphisms and Kir-Ligand Binding on Outcomes in Hematologic Malignancies Following Haploidentical Stem Cell Transplantation: A Comprehensive Review, Current Cancer Drug Targets (2023)
12. The Molecular Perspective on the Melanoma and Genome Engineering of T-Cells in Targeting Therapy, Environmental Research (2023)
13. Effect of Plasma-Derived Exosomes of Refractory/Relapsed or Responsive Patients With Diffuse Large B-Cell Lymphoma on Natural Killer Cells Functions, Cell Journal (2020)
14. Spirulina Extract Enriched for Braun-Type Lipoprotein (Immulina®) for Inhibition of 4T1 Breast Tumors' Growth and Metastasis, Phytotherapy Research (2020)
15. Safety and Feasibility of Blockade of Nk Group-2 Member-A Receptor in Natural Killer Cells Combined With Cetuximab Antibody in Patients With Advanced Gastric Adenocarcinoma, Advanced Pharmaceutical Bulletin (2025)
16. Strong Capacity of Differentiated Pd-L1 Car-Modified Ucb-Cd34+ Cells and Pd-L1 Car-Modified Ucb-Cd34+-Derived Nk Cells in Killing Target Cells and Restoration of the Anti-Tumor Function of Pd-1-High Exhausted T Cells, Stem Cell Research and Therapy (2024)
17. Immune Checkpoint Inhibition for the Treatment of Cancers: An Update and Critical Review of Ongoing Clinical Trials, Clinical Immunology (2021)
18. Advances in Bioengineered Car T/Nk Cell Therapy for Glioblastoma: Overcoming Immunosuppression and Nanotechnology-Based Strategies for Enhanced Car T/Nk Cell Therapy, Bioengineering and Translational Medicine (2025)
19. Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination With Checkpoint Inhibitors and Beyond, Current Drug Targets (2022)
20. Roles of Mesenchymal Stem Cells in Breast Cancer Therapy: Engineered Stem Cells and Exosomal Cell-Free Based Therapy, Current Molecular Medicine (2025)